TD Asset Management Inc Acquires 17,852 Shares of Merus N.V. $MRUS

Key Points

• TD Asset Management Inc increased its stake in Merus N.V. by 25.1% in Q2, owning 89,110 shares worth approximately $4.69 million after acquiring 17,852 additional shares.
• Merus recently reported a quarterly loss of ($2.23) earnings per share, falling short of analysts' expectations, along with revenue of $8.83 million against a consensus estimate of $9.77 million.
• The current market consensus for Merus N.V. stock is a "Hold" rating, with a price target averaging around $93.12.

TD Asset Management Inc grew its holdings in Merus N.V. (NASDAQ:MRUS - Free Report) by 25.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 89,110 shares of the biotechnology company's stock after acquiring an additional 17,852 shares during the quarter. TD Asset Management Inc owned 0.13% of Merus worth $4,687,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the business. Wellington Management Group LLP increased its holdings in shares of Merus by 34.9% in the first quarter. Wellington Management Group LLP now owns 4,718,172 shares of the biotechnology company's stock worth $198,588,000 after acquiring an additional 1,220,519 shares in the last quarter. Paradigm Biocapital Advisors LP increased its holdings in shares of Merus by 99.4% in the first quarter. Paradigm Biocapital Advisors LP now owns 3,369,699 shares of the biotechnology company's stock worth $141,831,000 after acquiring an additional 1,679,777 shares in the last quarter. Westfield Capital Management Co. LP increased its holdings in shares of Merus by 51.2% in the first quarter. Westfield Capital Management Co. LP now owns 1,501,220 shares of the biotechnology company's stock worth $63,186,000 after acquiring an additional 508,063 shares in the last quarter. Woodline Partners LP increased its holdings in shares of Merus by 17.8% in the first quarter. Woodline Partners LP now owns 1,400,171 shares of the biotechnology company's stock worth $58,933,000 after acquiring an additional 211,653 shares in the last quarter. Finally, Siren L.L.C. increased its holdings in shares of Merus by 33.0% in the first quarter. Siren L.L.C. now owns 1,043,467 shares of the biotechnology company's stock worth $43,920,000 after acquiring an additional 259,055 shares in the last quarter. 96.14% of the stock is currently owned by institutional investors.

Merus Stock Down 0.5%

MRUS stock opened at $94.44 on Tuesday. The business has a 50 day moving average price of $75.88 and a two-hundred day moving average price of $60.07. The company has a market cap of $7.14 billion, a price-to-earnings ratio of -17.17 and a beta of 1.26. Merus N.V. has a twelve month low of $33.19 and a twelve month high of $95.04.

Merus (NASDAQ:MRUS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biotechnology company reported ($2.23) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($1.06). The company had revenue of $8.83 million during the quarter, compared to the consensus estimate of $9.77 million. Merus had a negative net margin of 685.64% and a negative return on equity of 50.28%. On average, equities research analysts anticipate that Merus N.V. will post -3.85 EPS for the current fiscal year.

Analyst Ratings Changes

MRUS has been the subject of several recent analyst reports. Lifesci Capital restated a "market perform" rating and issued a $97.00 price target on shares of Merus in a report on Tuesday, September 30th. Canaccord Genuity Group downgraded Merus from a "buy" rating to a "hold" rating and increased their price objective for the stock from $67.00 to $97.00 in a report on Monday, September 29th. Truist Financial downgraded Merus from a "buy" rating to a "hold" rating and increased their price objective for the stock from $88.00 to $97.00 in a report on Monday, September 29th. Barclays reiterated an "equal weight" rating and set a $97.00 price objective (down from $112.00) on shares of Merus in a report on Tuesday, September 30th. Finally, HC Wainwright downgraded Merus from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $135.00 to $97.00 in a report on Monday, September 29th. Four investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $93.12.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

Want to see what other hedge funds are holding MRUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merus N.V. (NASDAQ:MRUS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.